var data={"title":"Epoprostenol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Epoprostenol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6117?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=epoprostenol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Epoprostenol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=epoprostenol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Epoprostenol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165855\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flolan;</li>\n      <li>Veletri</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165856\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Caripul;</li>\n      <li>Flolan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165879\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Prostacyclin;</li>\n      <li>\n        Prostaglandin;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165858\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary arterial hypertension (PAH):</b> IV: Initial: 2 ng/kg/minute; a lower initial dose may be used if patient is intolerant of starting dose. Increase dose in increments of 1 to 2 ng/kg/minute at intervals of &ge;15 minutes until dose-limiting side effects (eg, flushing, jaw pain, headache, hypotension, nausea) are noted or response to epoprostenol plateaus. The dose may also be lowered by 1 to 2 ng/kg/minute every 15 minutes to a dose that is tolerated (Bishop 2012). Usual optimal dose (monotherapy): 25 to 40 ng/kg/minute (McLaughlin 2009); significant patient variability in optimal dose exists. Maximum dose with chronic therapy has not been defined; however, doses as high as 195 ng/kg/minute have been described in children (Rosenzweig 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dose adjustment during chronic phase of treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If PAH symptoms persist or recur following improvement, increase dose in 1 to 2 ng/kg/minute increments at intervals of &ge;15 minutes. May also increase dose at intervals of 24 to 48 hours or longer (eg, every 1 to 2 weeks). <b>Note:</b> The need for increased doses should be expected with chronic use; incremental increases occur more frequently during the first few months after the drug is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In case of dose-limiting pharmacologic events (eg, hypotension, severe nausea, vomiting), decrease dose in 2 ng/kg/minute decrements at intervals of &ge;15 minutes until dose-limiting effects resolve. Avoid abrupt withdrawal or sudden large dose reductions. <b>Note:</b> Adverse event may resolve without dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lung transplant: In patients receiving lung transplants, epoprostenol may be tapered after sequential lung transplantation once the allografts have been reperfused. If cardiopulmonary bypass utilized, epoprostenol may be tapered after pump perfusion has been initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute vasodilator testing in patients with PAH (off-label use):</b> <b>Note:</b> Acute vasodilator testing should only be done in patients who might be considered candidates for calcium channel blocker therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 2 ng/kg/minute; increase dose in increments of 2 ng/kg/minute every 10 to 15 minutes; dosing range during testing: 2 to 12 ng/kg/minute (ACC/AHA [McLaughlin 2009]; ESC/ERS [Gali&egrave; 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoxia secondary to acute respiratory distress syndrome (off-label use): </b>Inhalation (off-label): Initial: 0.01 to 0.05 <b>mcg</b>/kg/minute; increase dose in stepwise fashion based on efficacy and tolerability. Wean by reducing dose by 0.01 <b>mcg</b>/kg/minute every 1 to 2 hours as tolerated (Ammar 2015; Torbic 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraoperative pulmonary hypertension during cardiac surgery with cardiopulmonary bypass (CPB) (off-label use):</b> Inhalation (off-label route): <b>Note:</b> Institution-specific protocols vary. Studies included utilized Flolan brand; however, formulary status of epoprostenol formulations may vary with some institutions utilizing Veletri, the more thermostable formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administration after induction of anesthesia before incision: 60 <b>mcg</b> (4 mL of 15,000 ng/mL concentration) via jet nebulizer; effect persists for ~25 minutes (Hache 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intraoperative administration: <i>Nebulization via ventilator circuit:</i> Using a 15,000 ng/mL concentration and an oxygen flow of 8 L/minute, begin administration via jet nebulizer 5 minutes prior to weaning from CPB; discontinue at least 60 minutes after CPB weaned (Fattouch 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-cardiothoracic surgery pulmonary hypertension, right ventricular dysfunction, or refractory hypoxemia (off-label use) (DeWet 2004): </b>Inhalation (off-label route): Study utilized Flolan brand; however, formulary status of epoprostenol formulations may vary with some institutions utilizing Veletri, the more thermostable  formulation. If using Flolan, may need to change ventilator filter every 2 hours due to glycine buffer diluent  ; may cause ventilator valve malfunction. Tidal volume delivered by ventilator may require adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nebulization via ventilator circuit:</i> Using a 20,000 ng/mL concentration, prime nebulizer chamber with 15 mL; administer remainder at a constant rate of 8 mL/hour; delivers ~38 ng/kg/minute (based on a 70 kg patient); set oxygen flow at 2 to 3 L/minute; wean as tolerated. <b>Note:</b> Although not achieved with this regimen, in general, doses &gt;50 ng/kg/minute do not provide additional benefit, may increase the risk of hypotension, and should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nebulization via facemask with Venturi attachment:</i> Using a 20,000 ng/mL concentration, prime nebulizer chamber with 15 mL; set oxygen flow at 2 to 3 L/minute; 8 mL/hour will be nebulized; wean as tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weaning procedure: Reduce dose by 50% every 2 to 4 hours (ie, 20,000 ng/mL to 10,000 ng/mL to 5,000 ng/mL) until a concentration of 2,500 ng/mL is reached; carefully discontinue once patient remains stable on this concentration for at least 4 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521393\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=epoprostenol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Epoprostenol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pulmonary arterial hypertension (PAH): </b> Children (off-label use) and Adolescents (off-label use): Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165859\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822433\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822434\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165839\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flolan: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Veletri: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg (1 ea); 1.5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165823\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20856518\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Caripul: 0.5 mg (1 ea); 1.5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11233737\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Orders for epoprostenol are distributed by two sources in the United States. Information on orders or reimbursement assistance may be obtained from either Accredo Health, Inc (1-866-344-4874) or CVS Caremark (1-877-242-2738). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165841\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: For IV use via an infusion pump. Use infusion sets with an in-line 0.22 micron filter. When administered on an ongoing basis, must be infused through a central venous catheter. Peripheral infusion may be used temporarily until central line is established. Do not administer as a bolus injection. Avoid abrupt withdrawal (including interruptions in delivery) or sudden large reductions in dosing. The ambulatory infusion pump should be small and lightweight, be able to adjust infusion rates in 2 ng/kg/minute increments, have occlusion, end of infusion, and low battery alarms, have &plusmn; 6% accuracy of the programmed rate, and have positive continuous or pulsatile pressure with intervals &le;3 minutes between pulses. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Immediate access to back up pump, infusion sets and medication is essential to prevent treatment interruptions. Consult manufacturer&rsquo;s labeling for infusion rate example calculations.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Inhalation (off-label route):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Intraoperative administration: Administer via jet nebulizer connected to the inspiratory limb of the ventilator near the endotracheal tube with a bypass oxygen flow of 8 L/minute to achieve administration of a high proportion of small particles (Fattouch 2006; Hache 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Post-cardiothoracic surgery: May also be administered via jet nebulizer connected to the inspiratory limb of the ventilator near the endotracheal tube or via face mask with a Venturi attachment for aerosolization with a bypass oxygen flow of 2 to 3 L/minute (De Wet 2004). <b>Note:</b> Glycine buffer diluent may cause ventilator valve malfunction; it has been recommended that filters be changed on the ventilator every 2 hours; may also use a ventilator heating coil (De Wet 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165840\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pulmonary arterial hypertension:</b> Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise capacity. <b>Note:</b> According to treatment guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) and the American College of Chest Physicians (ACCP), continuous IV epoprostenol is recommended as first-line therapy in PAH patients with WHO-FC IV symptoms (ACCP [Taichman 2014]; WSPH [Gail&egrave; 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725538\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute vasodilator testing in pulmonary arterial hypertension; Hypoxia secondary to acute respiratory distress syndrome; Pulmonary arterial hypertension related to cardiopulmonary bypass</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174529\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165830\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Adverse events reported during dose initiation and escalation include flushing (58%), headache (49%), nausea/vomiting (32%), hypotension (16%), anxiety/nervousness/agitation (11%), chest pain (11%); dizziness, abdominal pain, bradycardia, musculoskeletal pain, dyspnea, back pain, diaphoresis, dyspepsia, hypoesthesia/paresthesia, and tachycardia are also reported. Although some adverse reactions may be related to the underlying disease state, abdominal pain, anxiety/nervousness/agitation, arthralgia, bleeding, bradycardia, diarrhea, diaphoresis, flu-like syndrome, flushing, headache, hypotension, jaw pain, nausea, pain, pulmonary edema, rash, tachycardia, thrombocytopenia, and vomiting are clearly contributed to epoprostenol. The following adverse events have been reported during chronic administration for idiopathic or heritable PAH:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Tachycardia (35% to 43%), flushing (23% to 42%), hypotension (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (83%), headache (46% to 83%), chills (25%), fever (25%), flu-like syndrome (25%), sepsis (25%), anxiety (21%), nervousness (21%), tremor (21%), agitation (11%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Dermal ulcer (39%), eczema (25%), skin rash (25%), urticaria (25%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (&le;67%), vomiting (&le;67%), anorexia (66%), diarrhea (37% to 50%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reactions: Infection (18%), pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (&le;84%), neck pain (&le;84%), pain (&le;84%), jaw pain (54% to 75%), myalgia (44%), musculoskeletal pain (35%), hyperesthesia (&le;12%), hypoesthesia (&le;12%), paresthesia (&le;12%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anemia, ascites, bradycardia, diaphoresis, dyspnea, fatigue, hemorrhage, hepatic failure, hypersplenism, hyperthyroidism, pallor, pancytopenia, pulmonary edema, pulmonary embolism, splenomegaly, thrombocytopenia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165844\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to epoprostenol, to structurally-related compounds, or any component of the formulation; chronic use in patients with heart failure due to severe left ventricular systolic dysfunction; chronic use in patients who develop pulmonary edema during dose initiation (Veletri and Caripul [Canadian product] only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165827\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: Some patients with PAH have developed pulmonary edema during dosing adjustment and acute vasodilator testing (an off-label use), which may be associated with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. If pulmonary edema develops during therapy initiation, discontinue and do not readminister.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rebound pulmonary hypertension: Avoid abrupt interruptions or large sudden reductions in dosage; may result in rebound pulmonary hypertension (eg, dyspnea, dizziness, asthenia). A fatal case occurred following interruption. Immediate access to medication or pump and infusion sets is essential to prevent treatment interruptions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasodilation: Epoprostenol is a potent pulmonary and systemic vasodilator and can cause hypotension and other reactions such as flushing, nausea, vomiting, dizziness, and headache. Monitor blood pressure and symptoms regularly during initiation and after dose change.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions that increase bleeding risk: Epoprostenol is a potent inhibitor of platelet aggregation. Use with caution in patients with other risk factors for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate Use: Initiation or transition to epoprostenol requires specialized cardiopulmonary monitoring in a critical care setting where clinicians are experienced in advanced management of pulmonary arterial hypertension. To reduce the risk of thromboembolism during chronic use, anticoagulants should be coadministered unless contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Chronic continuous IV infusion of epoprostenol via a chronic indwelling central venous catheter (CVC) has been associated with local infections and serious blood stream infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299275\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165832\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9411&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Epoprostenol may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165834\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521390\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Women with pulmonary arterial hypertension (PAH) are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617104\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if epoprostenol is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer of Flolan and of Caripul [Canadian product] recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. The manufacturer of Veletri recommends that caution be exercised when administering epoprostenol to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165836\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for improvements in pulmonary function, decreased exertional dyspnea, fatigue, syncope and chest pain, blood pressure, pulmonary vascular resistance, pulmonary arterial pressure and quality of life. Following establishment of a new chronic infusion rate, measure standing and supine blood pressure for several hours. In addition, the pump device and catheters should be monitored frequently to avoid &ldquo;system&rdquo; related failure. Monitor arterial pressure; assess all vital functions. Hypoxia, flushing, and tachycardia may indicate overdose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165826\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Epoprostenol is also known as prostacyclin and PGI<sub>2</sub>. It is a strong vasodilator of all vascular beds. In addition, it is a potent endogenous inhibitor of platelet aggregation. The reduction in platelet aggregation results from epoprostenol's activation of intracellular adenylate cyclase and the resultant increase in cyclic adenosine monophosphate concentrations within the platelets. Additionally, it is capable of decreasing thrombogenesis and platelet clumping in the lungs by inhibiting platelet aggregation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165843\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly hydrolyzed; subject to some enzymatic degradation; forms two active metabolites (6-keto-prostaglandin F<sub>1</sub>&alpha; and 6,15-diketo-13,14-dihydro-prostaglandin F<sub>1</sub>&alpha;) with minimal activity and 14 inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~6 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (84%); feces (4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323130\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Epoprostenol Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $19.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $46.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Flolan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $22.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $54.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Veletri Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $28.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $56.21</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038611\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dynovase (ES);</li>\n      <li>Flolan (AT, AU, BE, CH, CZ, DK, EE, ES, FR, GB, GR, IE, IL, IT, LU, MT, NL, NO, PL, SG, TW);</li>\n      <li>Veletri (ES, GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26187741\"></a>Ammar MA, Bauer SR, Bass SN, Sasidhar M, Mullin R, Lam SW. Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS. <i>Ann Pharmacother</i>. 2015;49(10):1105-1112. doi: 10.1177/1060028015595642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/26187741/pubmed\" target=\"_blank\" id=\"26187741\">26187741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Maislin G, and Fishman AP, &ldquo;Vasodilator Therapy for Primary Pulmonary Hypertension in Children,&rdquo; <i>Circulation</i>, 1999, 99(9):1197-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/10069788/pubmed\" target=\"_blank\" id=\"10069788\">10069788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Rubin LJ, Long WA, et al, &ldquo;A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) With Conventional Therapy for Primary Pulmonary Hypertension. The Primary Pulmonary Hypertension Study Group,&rdquo; <i>N Engl J Med</i>, 1996, 334(5):296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/8532025/pubmed\" target=\"_blank\" id=\"8532025\">8532025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bishop BM, Mauro VF, Khouri SJ. Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. <i>Pharmacotherapy</i>. 2012;32(9):838-855. doi: 10.1002/j.1875-9114.2012.01114.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/22806762/pubmed\" target=\"_blank\" id=\"22806762\">22806762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caripul (epoprostenol) [product monograph]. Laval, Quebec, Canada: Actelion Pharmaceuticals Ltd; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cremona G and Higenbottam T, &ldquo;Role of Prostacyclin in the Treatment of Primary Pulmonary Hypertension,&rdquo; <i>Am J Cardiol</i>, 1995, 75(3):67A-71A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/7840058/pubmed\" target=\"_blank\" id=\"7840058\">7840058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15052203\"></a>De Wet CJ, Affleck DG, Jacobsohn E, et al, &ldquo;Inhaled Prostacyclin is Safe, Effective, and Affordable in Patients with Pulmonary Hypertension, Right Heart Dysfunction, and Refractory Hypoxemia After Cardiothoracic Surgery,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 2004, 127(4):1058-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/15052203/pubmed\" target=\"_blank\" id=\"15052203\">15052203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16645371\"></a>Fattouch K, Sbraga F, Sampognaro R, et al, &ldquo;Treatment of Pulmonary Hypertension in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized, Prospective, Double-Blind Study,&rdquo; <i>J Cardiovasc Med (Hagerstown)</i>, 2006, 7(2):119-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/16645371/pubmed\" target=\"_blank\" id=\"16645371\">16645371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flolan (epoprostenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flolan (epoprostenol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25 Suppl):D60-D72. doi: 10.1016/j.jacc.2013.10.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/24355643/pubmed\" target=\"_blank\" id=\"24355643\">24355643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26320113\"></a>Gali&egrave; N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>Eur Heart J</i>. 2016;37(1):67-119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/26320113/pubmed\" target=\"_blank\" id=\"26320113\">26320113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12658208\"></a>Hach&eacute;, M, Denault A, B&eacute;lisle S, et al, &ldquo;Inhaled Epoprostenol (Prostacyclin) and Pulmonary Hypertension Before Cardiac Surgery,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 2003, 125(3):642-9<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/12658208/pubmed\" target=\"_blank\" id=\"12658208\">12658208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higenbottam TW, Spiegelhalter D, Scott JP, et al, &ldquo;Prostacyclin (Epoprostenol) and Heart-Lung Transplantation as Treatments for Severe Pulmonary Hypertension,&rdquo; <i>Br Heart J</i>, 1994, 70:366-70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones DK, Higenbottam TW, and Wallwork J, &ldquo;Treatment of Primary Pulmonary Hypertension Intravenous Epoprostenol (Prostacyclin),&rdquo; <i>Br Heart J</i> 1987, 57(3):270-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26438636\"></a>McGinn K, Reichert M. A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery. <i>Ann Pharmacother</i>. 2016;50(1):22-26. doi: 10.1177/1060028015608865.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/26438636/pubmed\" target=\"_blank\" id=\"26438636\">26438636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo; <i>Circulation</i>, 2009, 119(16):2250-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/19332472/pubmed\" target=\"_blank\" id=\"19332472\">19332472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Genthner DE, Panella MM, et al, &ldquo;Reduction in Pulmonary Vascular Resistance With Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension,&rdquo; <i>N Engl J Med</i>, 1998, 338(5):273-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/9445406/pubmed\" target=\"_blank\" id=\"9445406\">9445406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Shillington A, and Rich S, &ldquo;Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy,&rdquo; <i>Circulation</i>, 2002, 106(12):1477-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/12234951/pubmed\" target=\"_blank\" id=\"12234951\">12234951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakayama T, Shimada H, Takatsuki S, et al, &ldquo;Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children,&rdquo; <i>Circ J</i>, 2007, 71(11):1785-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/17965503/pubmed\" target=\"_blank\" id=\"17965503\">17965503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rich S, Kaufmann E, and Levy PS, &ldquo;The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,&rdquo; <i>N Engl J Med,</i> 1992, 327(2):76-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/1603139/pubmed\" target=\"_blank\" id=\"1603139\">1603139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenzweig EB and Barst RJ, &ldquo;Idiopathic Pulmonary Arterial Hypertension in Children,&rdquo; <i>Curr Opin Pediatr</i>, 2005, 17(3):372-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/15891429/pubmed\" target=\"_blank\" id=\"15891429\">15891429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenzweig EB, Kerstein D, and Barst RJ, &quot;Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects,&quot; <i>Circulation</i>, 1999, 99(14):1858-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/10199883/pubmed\" target=\"_blank\" id=\"10199883\">10199883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenzweig EB, Widlitz AC, and Barst RJ, &ldquo;Pulmonary Arterial Hypertension in Children,&rdquo; <i>Pediatr Pulmonol</i>, 2004, 38(1):2-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/15170869/pubmed\" target=\"_blank\" id=\"15170869\">15170869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LJ, Groves BM, Reeves JT, et al, &ldquo;Prostacyclin-Induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension,&rdquo; <i>Circulation</i>, 1982, 66(2):334-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/7046988/pubmed\" target=\"_blank\" id=\"7046988\">7046988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitbon O, Humbert M, Nunes H, et al, &ldquo;Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension - Prognostic Factors and Survival,&rdquo; <i>J Am Coll Cardiol</i>, 2002, 40(40):780-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/12204511/pubmed\" target=\"_blank\" id=\"12204511\">12204511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sueta CA, Gheorghiade M, Adams KF, et al, &ldquo;Safety and Efficacy of Epoprostenol in Patients With Severe Congestive Heart Failure. Epoprostenol Multicenter Research Group,&rdquo; <i>Am J Cardiol</i>, 1995, 75(3):34A-43A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/7840053/pubmed\" target=\"_blank\" id=\"7840053\">7840053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/24937180/pubmed\" target=\"_blank\" id=\"24937180\">24937180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26668204\"></a>Torbic H, Szumita PM, Anger KE, Nuccio P, Lagambina S, Weinhouse G. Clinical and Economic Impact of Formulary Conversion From Inhaled Flolan to Inhaled Veletri for Refractory Hypoxemia in Critically Ill Patients. <i>Ann Pharmacother</i>. 2016;50(2):106-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/26668204/pubmed\" target=\"_blank\" id=\"26668204\">26668204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23683572\"></a>Torbic H, Szumita PM, Anger KE, Nuccio P, LaGambina S, Weinhouse G. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. <i>J Crit Care</i>. 2013;28(5):844-848. doi: 10.1016/j.jcrc.2013.03.006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/23683572/pubmed\" target=\"_blank\" id=\"23683572\">23683572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10713012\"></a>van Heerden PV, Barden A, Michalopaoulos N, et al, &ldquo;Dose-Response to Inhaled Aerosolized Prostacyclin for Hypoxemia Due to ARDS,&rdquo; <i>Chest</i>, 2000, 117(3):819-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/10713012/pubmed\" target=\"_blank\" id=\"10713012\">10713012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veletri (epoprostenol) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walmrath D, Schneider T, Pilch J, et al, &ldquo;Aerosolised Prostacyclin in Adult Respiratory Distress Syndrome,&rdquo; <i>Lancet</i>, 1993, 342(8877):961-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/8105216/pubmed\" target=\"_blank\" id=\"8105216\">8105216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widlitz A and Barst RJ, &ldquo;Pulmonary Arterial Hypertension in Childrenl,&rdquo;<i>Eur Respir J</i>, 2003, 21(1):155-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/12570125/pubmed\" target=\"_blank\" id=\"12570125\">12570125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zwissler, B, Kemming G, Habler O, et al, &ldquo;Inhaled Prostacyclin (PGI2) Versus Inhaled Nitric Oxide in Adult Respiratory Distress Syndrome,&rdquo; <i>Am J Respir Crit Care Med</i>, 1996, 154(6 Pt 1):1671-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-drug-information/abstract-text/8970353/pubmed\" target=\"_blank\" id=\"8970353\">8970353</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9411 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165855\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F165856\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F165879\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F165858\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2521393\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F165859\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15822433\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15822434\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165839\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F165823\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F20856518\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11233737\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F165841\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F165840\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725538\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174529\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165830\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165844\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165827\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299275\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F165832\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165834\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2521390\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617104\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F165836\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165826\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F165843\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323130\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038611\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9411|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=epoprostenol-patient-drug-information\" class=\"drug drug_patient\">Epoprostenol: Patient drug information</a></li><li><a href=\"topic.htm?path=epoprostenol-pediatric-drug-information\" class=\"drug drug_pediatric\">Epoprostenol: Pediatric drug information</a></li></ul></div></div>","javascript":null}